Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Income Before Tax

Profit after all operating and non-operating items but before income tax.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax remains negative

Q3 FY2026 income before tax was -$96.12M, compared with -$11.18M a year earlier. Trailing-twelve-month income before tax was -$263.86M.

Context

  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$96.12M or moves back toward the trailing-twelve-month quarterly average of -$65.96M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$96.12M-165.5% QoQ
Last fiscal yearDec 2025
-$155.22M+25.4% YoY
LTMSep 2026
-$263.86M-77.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-759.5%——
1 year+25.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(155.22M) USD
Year-over-year change
+25.4%

Income Before Tax vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -77.1% is the 6th highest of 9, against a peer median of -9.0%.
  • Income before tax amounts to 291.6% of revenue for SYRE, versus a peer median of 832.6%.
SYRE Competitors
Income Before Tax for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026-$26.63M USD+81.1%—11.5%
IFRXInflaRx N.V.LTM Mar 2026-€42.81M EUR+1.7%—145945.5%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024-€46.26M EUR-285.2%——
ARDXArdelyx, Inc.LTM Mar 2026-$57.94M USD-9.8%—13.5%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
IMUXImmunic, Inc.LTM Mar 2026-$104.29M USD-8.2%——
UPBUpstream Bio, Inc.LTM Mar 2026-$156.76M USD-98.0%—4719.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026-$263.86M USD-77.1%—291.6%
ABVXAbivax S.A.FY2025-€330.25M EUR-87.4%——
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding SYRE) —-9.0%—832.6%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.74M2.33M886K00
Cost of Revenue0000171.65M
Gross Profit18.74M2.33M886K0(171.65M)
Gross Margin100.0%100.0%100.0%——
Research & Development57.07M58.58M89.5M162.79M171.65M
Selling, General & Admin27.32M28.53M39.95M45.78M47.91M
Operating Expenses84.39M87.11M243.19M208.57M37.91M
Depreciation & Amortization1.58M1.96M744K010M
EBITDA(64.08M)(81.99M)(127.82M)(207.97M)(209.56M)
EBITDA Margin-342.0%-3520.3%-14426.6%——
Operating Income(65.65M)(84.78M)(242.3M)(208.57M)(209.56M)
Operating Margin-350.3%-3640.2%-27348.0%——
Interest Income111K837K6.15M21.31M24.89M
Interest Expense00000
Other Income / Expenses(11K)830K(96.51M)599K54.34M
Income Before Tax(65.66M)(83.95M)(338.82M)(207.97M)(155.22M)
Pre-Tax Margin-350.4%-3604.6%-38241.1%——
Income Tax Expense141K(136K)(26K)51K(15K)
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Net Margin-351.1%-3598.8%-38238.1%——
EPS (Basic)(25.02)(24.86)(46.15)(3.18)(1.98)
EPS (Diluted)(25.02)(24.86)(46.15)(3.18)(1.98)
Weighted Avg Shares2.63M3.37M6.9M47.03M64.06M
Weighted Avg Shares (Diluted)2.63M3.37M6.9M47.03M64.06M

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.